» Articles » PMID: 577076

Interaction of Rifampicin Treatment with Pharmacokinetics and Metabolism of Ethinyloestradiol in Man

Overview
Specialty Endocrinology
Date 1977 May 1
PMID 577076
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

[6,7-3H]Ethinyloestradiol (50 microng) was administered intravenously to volunteers and the free extractable ethinyloestradiol in the plasma was measured. The compound showed a biphasic plasma decline. The half-life of the second phase was 7.5+/-1.7 (SD) hours. Administration of rifampicin (600 mg for 6 days) shifted the half-life of ethinyloestradiol to 3.3+/-0.9 h while the apparent volume of distribution for the second phase of elimination was not changed. When [2,4,6,7-3H]ethinyloestradiol (100 microng) was administered orally, some of the tritium was released by oxidative metabolism from the steroid and transformed to tritiated water (HTO) which equilibrated with whole body water. This portion, normally 7.17+/-1.66% of the tritium dose, was increased by previous administration of rifampicin to 10.62+/-2.27%. The initial rate of oxication of [2,4,6,7-3H]ethinyloestradiol was increased more than twofold by rifampicin treatment. The results are consistent with previous findings that rifampicin induces the oestrogen-2-hydroxylase in the endoplasmic reticulum of human liver, and explain the reduced effectiveness of ethinyloestradiol in oral contraceptives, if the patients are treated with rifampicin.

Citing Articles

U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.

Nguyen A, Curtis K, Tepper N, Kortsmit K, Brittain A, Snyder E MMWR Recomm Rep. 2024; 73(4):1-126.

PMID: 39106314 PMC: 11315372. DOI: 10.15585/mmwr.rr7304a1.


Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism.

Guengerich F Pharmacol Rev. 2024; 76(6):1104-1132.

PMID: 39054072 PMC: 11549934. DOI: 10.1124/pharmrev.124.001173.


Roles of cytochrome P450 enzymes in pharmacology and toxicology: Past, present, and future.

Guengerich F Adv Pharmacol. 2022; 95:1-47.

PMID: 35953152 PMC: 9869358. DOI: 10.1016/bs.apha.2021.12.001.


Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications.

Guengerich F Biomol Ther (Seoul). 2021; 30(1):1-18.

PMID: 34475272 PMC: 8724836. DOI: 10.4062/biomolther.2021.102.


Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Females.

Landry I, Aluri J, Hall N, Filippov G, Dayal S, Moline M Clin Pharmacol Drug Dev. 2021; 10(9):1089-1098.

PMID: 34107159 PMC: 8453935. DOI: 10.1002/cpdd.953.